aytubio.com (AYTU) Cash per Single Share

Symbol and logo of brand Aytu Therapeutics (AYTU)

Asset restructuring to prioritize profitable pediatric products minimizes current losses despite pressure from insurance companies. Stable revenue is supported by inelastic demand for ADHD therapy. The cash per share metric visualizes this financial reserve, where the 2.36 mark reflects the latest data. The integration of long-acting medications into pediatric medicine creates a solid foundation for the business development of Aytu BioPharma (AYTU).

Aytu Therapeutics (AYTU): Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Aytu BioPharma Inc (AYTU)

- share price and expert price forecast:
- cash and cash flow data:
General company analysis:AYTU, Aytu Therapeutics
Original product of Aytu BioPharma

Cash per share determines the volume of liquid capital attributable to a single security. For Aytu BioPharma, Inc. (AYTU), this resource ensures the stable maintenance of its commercial staff and compliance officers. This cash per share chart reflects the company's ability to fund operating activities without emergency borrowings. An increase in this metric reduces financial risks, although excess cash may signal investment stagnation. Investors should interpret this metric as an indicator of solvency and the business's strategic margin of safety.